Spare a thought for your Scandinavian colleagues who are running CROs
Spare a thought for your Scandinavian colleagues who are running CROs: staff turnover among companies in Norway was 47% in 2015, and the comparable figure for Denmark was 43%, according to the 18th annual CRO Industry Global Compensation and Turnover Survey conducted by HR+Survey Solutions, LLC.
More than half of the countries surveyed (24 of the 45) had average turnover of 20% or more. Others with high turnover rates were India (36%), New Zealand (33%), and Switzerland (30%), Taiwan (29%), Finland (28%), and China (28%).
In the U.S., overall staff turnover increased slightly to 20.1% in 2015 from 19.5% in 2014 for all positions in CROs. Turnover in the U.S. for clinical monitoring jobs at CROs remained high at 25.1% in 2015, compared with 25.4% in 2014, 16.4% in 2013, 24.4% in 2012, and 29.4% in 2011.
U.S. unemployment has continued to decline since it peaked in 2009, and currently is well below 5%. This means that CROs have an uphill battle identifying new talent sources.
“Turnover is a significant business issue; high turnover can undermine the relationship with a sponsor,” noted Judy Canavan, managing partner of HR+Survey Solutions and the author of the study. “Employees have figured out that changing jobs is the key to maximizing their compensation and rounding out their CV, companies need to create internal career opportunities.”
According to Canavan, the number of registered clinical trials has risen sharply from 24,921 in 2005 to 231,508 as of December 4, 2016 (source: http://clinicaltrials.gov/ct2/resources/trends).
Other findings of the survey were:
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.